Pharmaceuticals

Neurological Disorder Drugs Market Outlook For 2026–2030 Covering Growth Drivers And Industry Trends

May 1, 2026May 1, 2026 by Marketing Posting

The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.

How Large Will The Neurological Disorder Drugs Market Be By 2030 Compared To Its 2026 Market Size?

The neurological disorder drugs market size has demonstrated significant growth in recent years. It is anticipated to expand from $89.24 billion in 2025 to $94.49 billion in 2026, achieving a compound annual growth rate (CAGR) of 5.9%. The historical period’s growth can be ascribed to the increasing prevalence of epilepsy and neurodegenerative diseases, an aging global population, the continued use of symptomatic neurological drugs, the broadening of hospital-based neurological care, and enhanced diagnosis rates of neurological disorders.

The neurological disorder drugs market size is projected to experience substantial expansion in the coming years. By 2030, its valuation is anticipated to reach $116.27 billion, exhibiting a compound annual growth rate (CAGR) of 5.3%. This anticipated growth during the forecast period is attributable to several factors, including progress in neurological drug development pipelines, the increasing prevalence of Alzheimer’s and Parkinson’s disease, enhanced availability of neurological care in developing markets, an escalating need for individualized neurology treatments, and the wider availability of homecare and outpatient neurological therapies. Key trends projected for the forecast period encompass a greater uptake of disease-modifying neurological therapies, an increasing emphasis on prompt diagnosis and sustained disease management, a heightened requirement for combination drug treatments, the broadening scope of oral and home-based neurological interventions, and a stronger focus on alleviating symptoms and enhancing patients’ quality of life.

Access Your Free Sample Report For In-Depth Market Analysis:

https://www.thebusinessresearchcompany.com/sample.aspx?id=17207&type=smp

What Primary Drivers Are Shaping The Neurological Disorder Drugs Market?

The increasing incidence of neurological diseases is poised to stimulate the expansion of the neurological disorder drugs market in the coming years. Neurological disorders are conditions affecting the brain, spinal cord, and nerves, stemming from structural, biochemical, or electrical irregularities that manifest in various symptoms. The rise in these diseases is attributed to a growing global elderly population and heightened exposure to environmental, metabolic, and lifestyle risk factors. Neurological disorder drugs are vital in addressing these complex conditions, offering symptom alleviation, slowing disease progression, and enhancing long-term patient well-being. For example, according to the Australian Institute of Health and Welfare in September 2024, it is forecasted that the number of individuals with dementia in Australia will more than double between 2023 and 2058, rising from approximately 411,100 in 2023 to 849,300 by 2058, impacting around 315,500 men and 533,800 women. This growing prevalence of neurological diseases is thus a key driver for the neurological disorder drugs market.

What Are The Different Segment Types In The Neurological Disorder Drugs Market Segment Breakdown?

The neurological disorder drugs market covered in this report is segmented –

1) By Drug Class: Cholinesterase Inhibitors, N-Methyl-D-Aspartate (NMDA) Receptor Antagonists, Antiepileptic, Antipsychotic And Antidepressant, Other Drugs Classes

2) By Indication: Epilepsy, Alzheimer’s Disease, Parkinson’s Disease, Multiple Sclerosis, Cerebrovascular Disease, Other Indications

3) By Route Of Administration: Oral, Parenteral, Other Routes Of Administration

4) By Distribution Channel: Hospital Pharmacy, Retail Pharmacy, Online Pharmacy, Other Distribution Channels

5) By End-Users: Hospitals, Specialty Clinics, Homecare, Other End Users

Subsegments:

1) By Cholinesterase Inhibitors: Donepezil, Rivastigmine, Galantamine

2) By N-Methyl-D-Aspartate (NMDA) Receptor Antagonists: Memantine, Other NMDA Receptor Antagonists

3) By Antiepileptic: Sodium Channel Blockers, GABA Enhancers, Glutamate Modulators, Other Antiepileptics

4) By Antipsychotic and Antidepressant: Risperidone, Olanzapine, SSRIs, SNRIs, Tricyclic

5) By Other Drug Classes: Dopaminergic Drugs, Alpha-2 Agonists, Immunomodulators, Other Neurological Disorder Medications

What Trends Are Influencing The Neurological Disorder Drugs Market?

Leading companies within the neurological disorder drugs market are concentrating on advancing innovative remedies, such as those derived from Ocrelizumab, to elevate treatment efficacy, achieve better patient outcomes, and broaden therapeutic alternatives for individuals suffering from multiple sclerosis. Ocrelizumab itself is a humanized monoclonal antibody specifically engineered to target CD20-positive B cells, thereby contributing to a reduction in disease activity and a deceleration of progression in both relapsing and primary progressive forms of multiple sclerosis. For example, in September 2024, Roche Holding AG, a pharmaceutical company based in Switzerland, secured regulatory approval from the U.S. Food and Drug Administration (FDA) for OCREVUS ZUNOVO (ocrelizumab & hyaluronidase-ocsq). This formulation is a twice-yearly, approximately 10-minute subcutaneous injection, representing the first-ever subcutaneous Ocrevus version to gain approval for both relapsing (RMS) and primary progressive (PPMS) multiple sclerosis. This upgraded delivery option is intended to boost convenience, widen access to the therapy, and support clinical workflow efficiency by providing a quicker, non-intravenous method of administration.

Who Are The Well-Known Companies In The Neurological Disorder Drugs Market?

Major companies operating in the neurological disorder drugs market are F. Hoffmann-La Roche Ltd, Bayer AG, Sanofi S.A, AstraZeneca PLC, Abbott Laboratories, Novartis AG, GlaxoSmithKline plc, Takeda Pharmaceutical Company Limited, Eli Lilly and Company Pvt Ltd, Amgen Inc, Boehringer Ingelheim GmbH, Merck KGaA, Teva Pharmaceutical Industries Ltd, Otsuka America Pharmaceutical Inc, Biogen Inc, Bausch Health Companies Inc, Alexion Pharmaceuticals Inc., UCB S.A., Eisai Co Ltd, Cipla Inc, BioMarin Pharmaceutical Inc., Biocon Ltd, Acorda Therapeutics Inc.

Get The Full Neurological Disorder Drugs Market Report:

https://www.thebusinessresearchcompany.com/report/neurological-disorder-drugs-global-market-report

Where Is The Neurological Disorder Drugs Market Most Concentrated Geographically?

North America was the largest region in the neurological disorder drugs market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the neurological disorder drugs market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Customized Neurological Disorder Drugs Market Report For Competitive Insights:

https://www.thebusinessresearchcompany.com/report/neurological-disorder-drugs-global-market-report

Browse Through More Reports Similar to the Global Neurological Disorder Drugs Market 2026, By The Business Research Company

Neurological Disorder Drugs Market Report 2026

https://www.thebusinessresearchcompany.com/report/neurological-disorder-drugs-global-market-report

Central Nervous System Drug Market Report 2026

https://www.thebusinessresearchcompany.com/report/central-nervous-system-drug-global-market-report

Cholinergic Drugs Market Report 2026

https://www.thebusinessresearchcompany.com/report/cholinergic-drugs-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795